IPO Issue Details
Issue Price / Price Band₹96 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,200 Shares per Lot
Total Issue Size61,00,800 shares (aggregating up to ₹58.57 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE SME
IPO TypeSME
Subscription OpenWed, 18 Jun 2025
Subscription CloseFri, 20 Jun 2025
Anchor AllotmentTue, 17 Jun 2025
Basis of AllotmentMon, 23 Jun 2025
Initiation of RefundsTue, 24 Jun 2025
Credit of Shares to DematTue, 24 Jun 2025
Listing DateWed, 25 Jun 2025
UPI Mandate Deadline2025-06-20
Application & Investment Details
Retail — Min (1 Lots)₹1,15,200 — 1,200 shares
Retail — Max (13 Lots)₹1,497,600 (13 Lots)
HNI — Min (2 Lots)₹2,30,400 — 2,400 shares
EPS (Pre-IPO)₹7.36
EPS (Post-IPO)₹5.77
P/E Ratio (Pre-IPO)13.04x
P/E Ratio (Post-IPO)16.63x
Net Offer to Public57,94,800 shares (aggregating up to ₹55.63 Cr)
Reserved for Market Maker3,06,000 shares (aggregating up to ₹2.94 Cr)
Pre-IPO Promoter Holding1,81,50,000 shares
Post-IPO Promoter Holding2,31,50,400 shares
Fresh Issue Shares46,94,400 shares (aggregating up to ₹45.07 Cr)
Offer for Sale Shares11,00,400 shares of ₹10 (aggregating up to ₹10.56 Cr)
About Influx Healthtech Ltd
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing. The company is a reliable CDMO, providing specialized services to clients in multiple industries.The company has three manufacturing facilities in Thane, Maharashtra, each covering an area of 9,676 square feet, 13,000 square feet, and 14,000 square feet, respectively.Product Portfolio:Tablets, Capsules, and PowdersLiquid Orals and SoftgelsLozenges, Jellies, and GummiesOral Dispersible Films (ODFs)Effervescent Tablets and Liquid-Fill CapsulesCandies and Gym/Sports SupplementsSkin Care and Body Care ProductsHair Care and Beard Care SolutionsFace Masks and Soaps.Ayurvedic / Herbal formulationsVeterinary Feed SupplementsHomecare solutionsThe Company aids Nutraceutical and Cosmetic firms with product development and manufacturing. It offers end-to-end services, including development, production, and regulatory support, enabling clients to focus on formulation and commercialization.As of June 11, 2025, the company has 163 permanent employees on a payroll basis.Competitive StrengthDiversified Product PortfolioDiverse ClienteleStringent Quality Assurance/Quality ControlExperienced and Qualified Promoters and Management team.
Objects of the Issue
Influx Healthtech Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division
22.60
2
Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division
11.59
3
Purchase of Machineries for Homecare and Cosmetic Division
2.76
4
General corporate purposes
5.44
Shareholding & Lock-in
Pre-IPO Promoter Holding
1,81,50,000 shares
Post-IPO Promoter Holding
2,31,50,400 shares